(0.17%) 5 189.70 points
(0.14%) 38 906 points
(-0.06%) 16 340 points
(0.01%) $78.49
(0.82%) $2.21
(-0.41%) $2 321.70
(-0.37%) $27.51
(2.49%) $988.90
(0.15%) $0.930
(0.73%) $10.90
(0.43%) $0.799
(-0.08%) $91.27
Live Chart Being Loaded With Signals
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders...
Stats | |
---|---|
今日成交量 | 300 150 |
平均成交量 | 511 646 |
市值 | 1.93B |
EPS | £0 ( 2024-04-24 ) |
下一个收益日期 | ( £0 ) 2024-07-25 |
Last Dividend | £36.50 ( 2016-06-16 ) |
Next Dividend | £0 ( N/A ) |
P/E | 1 422.00 |
ATR14 | £1.896 (0.13%) |
音量 相关性
Indivior PLC 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Indivior PLC 相关性 - 货币/商品
Indivior PLC 财务报表
Annual | 2023 |
营收: | £1.09B |
毛利润: | £907.00M (82.98 %) |
EPS: | £0.0100 |
FY | 2023 |
营收: | £1.09B |
毛利润: | £907.00M (82.98 %) |
EPS: | £0.0100 |
FY | 2022 |
营收: | £901.00M |
毛利润: | £742.00M (82.35 %) |
EPS: | £-0.380 |
FY | 2021 |
营收: | £791.00M |
毛利润: | £664.00M (83.94 %) |
EPS: | £1.410 |
Financial Reports:
No articles found.
Indivior PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
First Dividend | £10.40 | 2015-09-17 |
Last Dividend | £36.50 | 2016-06-16 |
Next Dividend | £0 | N/A |
Payout Date | 2016-07-29 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | £46.90 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.12 | -- |
Div. Sustainability Score | 4.95 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 1.992 | -- |
Year | Amount | Yield |
---|---|---|
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £0 | 0.00% |
2019 | £0 | 0.00% |
2020 | £0 | 0.00% |
2021 | £0 | 0.00% |
2022 | £0 | 0.00% |
2023 | £0 | 0.00% |
2024 | £0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TON.L | Dividend Knight | 2023-06-01 | Annually | 32 | 1.80% | |
LTHM.L | Dividend Knight | 2023-08-03 | Semi-Annually | 33 | 0.87% | |
COA.L | Dividend Knight | 2023-10-19 | Annually | 33 | 1.79% | |
ROR.L | Dividend Knight | 2023-08-17 | Semi-Annually | 32 | 1.43% | |
HHI.L | Dividend King | 2023-09-14 | Quarterly | 25 | 3.58% | |
AUTO.L | Dividend Knight | 2023-08-24 | Annually | 9 | 0.79% | |
VLX.L | Dividend Knight | 2023-07-20 | Sporadic | 32 | 0.82% | |
MRCH.L | Dividend King | 2023-07-06 | Quarterly | 53 | 3.07% | |
DIVI.L | Dividend Knight | 2023-09-28 | Quarterly | 14 | 1.99% | |
SHOE.L | Dividend Knight | 2023-07-13 | Annually | 10 | 2.57% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00183 | 1.500 | 9.96 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00102 | 1.200 | 9.97 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00542 | 1.500 | -1.051 | -1.576 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.968 | 0.800 | -0.161 | -0.129 | [1 - 3] |
quickRatioTTM | 0.526 | 0.800 | -1.609 | -1.287 | [0.8 - 2.5] |
cashRatioTTM | 0.242 | 1.500 | 9.77 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.144 | -1.500 | 7.59 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0.553 | 1.000 | -0.906 | -0.906 | [3 - 30] |
operatingCashFlowPerShareTTM | -2.29 | 2.00 | -0.764 | -1.528 | [0 - 30] |
freeCashFlowPerShareTTM | -2.68 | 2.00 | -1.339 | -2.68 | [0 - 20] |
debtEquityRatioTTM | 0.215 | -1.500 | 9.14 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.830 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0192 | 1.000 | -1.616 | -1.616 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1.117 | 1.000 | -7.32 | -7.32 | [0.2 - 2] |
assetTurnoverTTM | 0.559 | 0.800 | 9.60 | 7.68 | [0.5 - 2] |
Total Score | 4.95 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 1 238.72 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00542 | 2.50 | -0.676 | -1.576 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.68 | 2.00 | -0.892 | -2.68 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -2.29 | 2.00 | -0.764 | -1.528 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.288 | 1.000 | -9.70 | 0 | [0.1 - 0.5] |
Total Score | -0.971 |
Indivior PLC
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。